<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04476862</url>
  </required_header>
  <id_info>
    <org_study_id>190-501</org_study_id>
    <nct_id>NCT04476862</nct_id>
  </id_info>
  <brief_title>Cerliponase Alfa Observational Study in the US</brief_title>
  <official_title>Cerliponase Alfa Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioMarin Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioMarin Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, observational study for patients with a confirmed diagnosis of&#xD;
      neuronal ceroid lipofuscinosis type 2 (CLN2 disease), also known as TPP1 deficiency, who&#xD;
      intend to be or are currently being treated with cerliponase alfa. Patients receiving or&#xD;
      expected to receive cerliponase alfa within 60 days of signing the informed consent form&#xD;
      (ICF) may be eligible to enroll in the study, assuming all regulatory requirements for sites&#xD;
      that have agreed to participate and protocol inclusion criteria are met. Data may be&#xD;
      collected for all or some of the assessments as outlined in the protocol, dependent upon the&#xD;
      clinic's and/or individual patient's standard of care.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 19, 2020</start_date>
  <completion_date type="Anticipated">August 24, 2030</completion_date>
  <primary_completion_date type="Anticipated">August 24, 2030</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Safety surveillance of cerliponase alfa</measure>
    <time_frame>10 years</time_frame>
    <description>To evaluate the long-term safety of cerliponase alfa in patients with neuronal ceroid lipofuscinosis Type 2 (CLN2 disease).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypersensitivity</measure>
    <time_frame>10 years</time_frame>
    <description>To further assess the occurrence of serious hypersensitivity reactions (including anaphylaxis), serious cardiovascular adverse events, and serious device-related complications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe SAE impact on patient's motor and language functions</measure>
    <time_frame>10 years</time_frame>
    <description>To evaluate the effects of Grade III or higher serious adverse events (SAEs) on patient performance on the CLN2 clinical rating scale (motor and language domains).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2</condition>
  <arm_group>
    <arm_group_label>Cerliponase alfa patients</arm_group_label>
    <description>Patients who are currently on or plan to start taking cerliponase alfa within 60 days of signing the study informed consent form.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cerliponase Alfa</intervention_name>
    <description>Commercially available product provided to patient by participating clinic site.</description>
    <arm_group_label>Cerliponase alfa patients</arm_group_label>
    <other_name>Brineura</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Administration Kit</intervention_name>
    <description>Commercially available administration kit provided to the patient by participating clinic site.</description>
    <arm_group_label>Cerliponase alfa patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        CLN2 patients who are currently taking or intend to take cerliponase alfa within 60 days of&#xD;
        signing the informed consent form.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosed with CLN2 disease.&#xD;
&#xD;
          2. Currently receiving or plan to begin treatment with cerliponase alfa.&#xD;
&#xD;
          3. Written informed consent/assent obtained.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Currently receiving treatment in another investigational device or drug study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor, MD</last_name>
    <role>Study Director</role>
    <affiliation>BioMarin Pharmaceutical</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Specialist</last_name>
    <phone>+1.651.523.0310</phone>
    <email>medinfo@bmrn.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kapil Arya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Raymond Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Scott Demarest, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vikas Bhambhani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mt. Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jayesh Ganesh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jennifer Vermilion, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Emily De Los Reyes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>July 15, 2020</study_first_submitted>
  <study_first_submitted_qc>July 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2020</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Batten's Disease</keyword>
  <keyword>CLN2</keyword>
  <keyword>TPP1 enzyme</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuronal Ceroid-Lipofuscinoses</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

